首页> 外文期刊>International Journal of Radiation Oncology, Biology, Physics >Can elective nodal irradiation be omitted in stage III non-small-cell lung cancer? analysis of recurrences in a phase II study of induction chemotherapy and involved-field radiotherapy.
【24h】

Can elective nodal irradiation be omitted in stage III non-small-cell lung cancer? analysis of recurrences in a phase II study of induction chemotherapy and involved-field radiotherapy.

机译:III期非小细胞肺癌是否可以省略选择性淋巴结照射?诱导化学疗法和相关场放疗的II期研究中的复发分析。

获取原文
获取原文并翻译 | 示例
       

摘要

Purpose: To establish the recurrence patterns when elective mediastinal irradiation was omitted, patients with Stage III non-small-cell lung cancer were treated with sequential chemotherapy (CHT) and involved-field radiotherapy (RT).Methods and Materials: Fifty patients were treated with either two or four cycles of induction CHT, followed by once-daily involved-field RT to 70 Gy, delivered using three-dimensional treatment planning. The contoured gross tumor volume consisted of the pre-CHT tumor volume and nodes with a short-axis diameter of >/=1 cm. Patients were reevaluated at 3 and 6 months after RT using bronchoscopy and chest CT. Elective nodal failure was defined as recurrence in the regional nodes outside the clinical target volume, in the absence of in-field failure.Results: Of 43 patients who received doses >/=50 Gy, 35% were disease free at last follow-up; in-field recurrences developed in 27% (of whom 16% had exclusively in-field recurrences); 18% had distant metastases exclusively. No elective nodal failure was observed. The median actuarial overall survival was 18 months (95% confidence interval 14-22) and the median progression-free survival was 12 months (95% confidence interval 6-18).Conclusion: Omitting elective mediastinal irradiation did not result in isolated nodal failure. Future studies of concurrent CHT and RT for Stage III non-small-cell lung cancer should use involved-field RT to limit toxicity.
机译:目的:建立省略选择性纵隔放疗的复发模式,对III期非小细胞肺癌患者进行序贯化疗(CHT)和累及野放疗(RT)。方法和材料:治疗50例患者。进行2到4个周期的诱导CHT,然后每天进行一次涉及场的RT至70 Gy,采用三维治疗计划进行。轮廓轮廓的肿瘤总体积由CHT前肿瘤体积和短轴直径> / = 1 cm的淋巴结组成。在RT后3个月和6个月使用支气管镜和胸部CT对患者进行重新评估。选择性淋巴结衰竭定义为在没有目标衰竭的情况下在临床目标体积之外的区域结节复发。结果:43名接受剂量> / = 50 Gy的患者中,有35%的患者在最后一次随访中没有疾病;场内复发的发生率为27%(其中16%仅发生场内复发); 18%仅发生远处转移。没有观察到选择性的结节失败。中位精算总生存期为18个月(95%置信区间14-22),中位无进展生存期为12个月(95%置信区间6-18)。结论:省略选择性纵隔放疗不会导致单纯的淋巴结衰竭。 III期非小细胞肺癌同时进行CHT和RT的进一步研究应使用受累区域RT来限制毒性。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号